News & Updates
Filter by Specialty:
Long-term benefits with molnupiravir modest at best in COVID-19 treatment
The antiviral molnupiravir confers continued but modest benefits in terms of reducing COVID-19–related symptoms up to 6 months after the index infection in a vaccinated population, according to a secondary analysis of the PANORAMIC trial.
Long-term benefits with molnupiravir modest at best in COVID-19 treatment
24 Sep 2024
Laughter is ‘best’ medicine for dry eye disease
A recent study has found that laughing can be as effective as artificial tears (ie, 0.1% sodium hyaluronic acid eye drop) in relieving ocular surface discomfort in patients with dry eye disease (DED) with limited corneal staining.
Laughter is ‘best’ medicine for dry eye disease
24 Sep 2024
Long-term freedom from insulin may be achieved with duodenal electroporation plus semaglutide
The combination of re-cellularization via electroporation therapy (ReCET) plus semaglutide appears to improve glucose control and metabolic health and eliminate the need for insulin therapy in most patients with type 2 diabetes (T2D), with the effects maintained up to 2 years, according to the follow-up data from the single-arm, dose-finding, first-in-human EMINENT trial.